Technologies Licenciables / Liste des technologies licenciables
Licensing opportunity
DI 98/40

Monoclonal Antibody based ELISA for Interleukin-1 receptor antagonist (IL-1ra)

Inventor: Jean-Marc CAVAILLON et al.

 Description of invention:

Interleukin-1 receptor antagonist (IL-1ra) is a member of the IL-1 family. Endogenous IL-1ra is produced in numerous animal disease models as well as in human autoimmune and chronic inflammatory diseases. It binds to IL-1 receptors in competition with IL-1, but does not elicit intracellular response from this binding. Its role in counteracting the proinflammatory effects of IL-1 is being studied by numerous research groups. In addition, a recent study suggests that IL-1ra can be used as marker for the early diagnosis of neonatal sepsis.

Researchers at the Institut Pasteur have developed an immunoassay to measure IL-1ra in vitro or in body fluids. Two apparently identical murine monoclonal antibodies directed against human IL-1ra were produced. One of these antibodies, in combination with a polyclonal antibody generated by the investigators, was used in a sandwich ELISA to quantify the presence of IL-1ra in cell supernatants of activated cell cultures. The test’s sensitivity threshold was 30 pg/ml. Due to its sensitivity, it is believed that this assay would be suitable for measuring IL-1ra in cell cultures as well as in biological fluids. 

 
 Potential applications: 

 Diagnosis of inflammatory diseases (e.g. sepsis) using immunodetection of IL-1ra in biological fluids.
 Assessment of the effects of anti-inflammatory agents on expression of IL-1 and IL-1ra in vitro or in body fluids.


Contact : Christophe Poquet, Business Development Manager - Office of Technology Transfer
 Institut Pasteur – 28 Rue du Docteur Roux – 75724 Paris Cedex 15 FRANCE
Tel : 33 (0)1 40 61 33 97 - Fax : 33 (0)1 40.61.37.32 – email : cpoquet@pasteur.fr